

Characterization of Ileal Vitamin B₁₂ Binding Using Homogeneous Human and Hog Intrinsic Factors

DAVID C. HOOPER, DAVID H. ALPERS, ROBERT L. BURGER,
CAROL S. MEHLMAN, and ROBERT H. ALLEN

*From the Department of Internal Medicine, Washington University School of
Medicine, St. Louis, Missouri 63110*

ABSTRACT Elucidation of the mechanism of intrinsic factor (IF)-mediated vitamin B₁₂ (B₁₂) binding to ileal binding sites has been hampered by the use of crude or only partially purified preparations of IF in previous studies. We have used homogeneous human IF and hog IF isolated by affinity chromatography to study [⁵⁷Co]B₁₂ binding to ileal mucosal homogenates. The following observations were made: (a) Human IF-B₁₂ and hog IF-B₁₂ were bound to human, monkey, hog, dog, rabbit, mouse, hamster, and guinea pig ileal, but not jejunal, homogenates in amounts significantly greater than free B₁₂ or B₁₂ bound to five other homogeneous B₁₂-binding proteins; (b) only IF-mediated B₁₂ binding was localized to ileal homogenates and was inhibited by EDTA; (c) values for the association constant (K_a) for the various ileal homogenates mentioned above and human IF-B₁₂ and hog IF-B₁₂ ranged from $0.3 \times 10^9 \text{ M}^{-1}$ to $13.0 \times 10^9 \text{ M}^{-1}$. Apparent differences in the K_a for human IF-B₁₂ and hog IF-B₁₂ existed in most species; (d) the number of ileal IF-B₁₂ binding sites per gram (wet weight) of ileal mucosa ranged from 0.3×10^{12} to 4.9×10^{12} . The same value was always obtained with human IF-B₁₂ and hog IF-B₁₂ for any given homogenate preparation; (e) 100-fold excesses of free B₁₂ or human IF and hog IF devoid of B₁₂ did not significantly inhibit human IF-B₁₂ and hog IF-B₁₂ binding to human and hog ileal homogenates.

These experiments performed with homogeneous IF indicate that: (a) gastric factors other than IF are not required for B₁₂ binding to ileal IF-B₁₂-binding sites; (b) the mechanism of ileal IF-B₁₂ binding is different from that of free B₁₂ or of B₁₂ bound to non-IF-B₁₂-binding proteins; (c) human IF and hog IF have different structures; (d) human IF-B₁₂ and hog IF-B₁₂ bind to

the same ileal binding sites; and (e) human and hog ileal IF-B₁₂ binding sites bind free B₁₂ and human and hog IF devoid of B₁₂ poorly, if at all.

INTRODUCTION

In many animals, including man, the stomach synthesizes and secretes a glycoprotein known as intrinsic factor (IF)¹ that binds vitamin B₁₂ (B₁₂) and facilitates the absorption of the vitamin in the distal small intestine. The mechanism of IF-mediated B₁₂ absorption is not well understood, but a number of studies have demonstrated that IF facilitates B₁₂ binding to ileal sacs (1-6), mucosal homogenates (4, 7-10), microvillus membrane preparations (11, 12), and to a component solubilized from ileal mucosa with Triton X-100 (13). IF-facilitated B₁₂ binding of this type is dependent on pH, is inhibited by EDTA, and is postulated to represent the first step in the complex process by which B₁₂ passes from the intestinal lumen into the portal blood.

Previous studies of IF-facilitated ileal B₁₂ binding have employed crude or only partially purified preparations of IF, however, and for this reason a number of aspects of this phenomenon remain unclear. The areas of uncertainty include the following: (a) whether free B₁₂ and IF devoid of B₁₂ compete with the IF-B₁₂ complex for binding to ileal IF-B₁₂ binding sites (2, 7, 9, 11, 14, 15) or not (3, 6, 8, 16); (b) whether gastric factors other than IF are required for IF-B₁₂ binding to ileal binding sites as has been suggested (15); and (c) whether B₁₂-binding proteins lacking IF activity in

This work was presented in part at the Annual Meeting of the American Federation for Clinical Research, Atlantic City, New Jersey, April 28, 1973.

Received for publication 15 May 1973 and in revised form 30 July 1973.

¹Abbreviations used in this paper: B₁₂, vitamin B₁₂ (cyanocobalamin); IF, intrinsic factor vitamin B₁₂ binding protein; KRPO₄, Krebs-Ringer phosphate; KRPO₄-Ca⁺⁺/Mg⁺⁺, KRPO₄ lacking CaCl₂ and MgSO₄; KRPO₄-Ca⁺⁺/Mg⁺⁺+EDTA, KRPO₄-Ca⁺⁺/Mg⁺⁺ containing 0.001 M Na₂EDTA; NIF, gastric nonintrinsic factor B₁₂ binding protein.

Schilling tests bind to ileal IF-B₁₂ binding sites when complexed with B₁₂ (17). Binding studies using crude gastric preparations are difficult to interpret because of the presence of B₁₂ binding proteins that lack in vivo IF activity as well as the possible presence of additional gastric inhibitors or stimulators. Uncertainty also remains, therefore, with regard to (d) the affinity of the IF-B₁₂ complex for the ileal B₁₂ binding site; (e) the number of such binding sites present in ileal mucosa; and (f) the relative ability of IF obtained from different species to facilitate ileal B₁₂ binding (1, 2, 18, 19).

Because of the ambiguities enumerated above, we have studied IF-facilitated B₁₂-binding utilizing homogeneous preparations of human IF, hog IF, hog gastric non-IF B₁₂ binding protein (hog NIF), human plasma transcobalamin II, and B₁₂ binding proteins isolated from human saliva, milk, and granulocytes. This report is concerned with the results of these studies.

METHODS

Preparation of intestinal mucosal homogenates. Guinea pigs, rabbits, hamsters, mice, and rats were decapitated. The intestine from pylorus to cecum was removed and placed on ice, and the lumen was rinsed with ice-cold isotonic saline. The intestine was divided in half, and the mucosa was scraped from the nonverted segments with glass microscope slides in a manner similar to that described by Sullivan, Herbert, and Castle (7). Hog, monkey, dog, and bovine small intestines were obtained within 45 min of death and placed on ice. Appropriate segments were opened along the mesenteric border and rinsed gently in ice-cold isotonic saline, and the mucosa was scraped free with glass microscope slides. Segments of human jejunum and distal ileum were obtained from patients undergoing ileojejunal bypass for morbid obesity and placed on ice. These segments were processed, and the mucosa was scraped free as described above for the hog and other large animals.

Mucosal scrapings from individual intestinal segments of large animals, or from pooled corresponding segments of small animals, were weighed and suspended in 10 vol (vol/wt) of ice-cold 0.14 M NaCl, 0.005 M KCl, 0.0025 M CaCl₂, 0.00125 M MgSO₄, 0.005 M potassium phosphate pH 7.4 (Krebs-Ringer phosphate, KRPO₄). Each suspension was homogenized in a Waring blender (Waring Products Div., Dynamics Corp. of America, New Hartford, Conn.) for 30 s, divided into 10-ml aliquots, and stored at -20°C.

Homogenates were thawed immediately before use and were rehomogenized at 4°C with approximately 10 strokes of a motor-driven Teflon pestle in a fitted glass tube. Homogenates were centrifuged at 10,000g at 4°C, and the pellets were suspended with a Vortex mixer (Scientific Industries, Inc., Queens Village, N. Y.) in KRPO₄ lacking CaCl₂ and MgSO₄ (KRPO₄-Ca⁺⁺/Mg⁺⁺) and recentrifuged. The pellet was washed twice more, and sufficient KRPO₄-Ca⁺⁺/Mg⁺⁺ was added to the final pellet to make the total value equal to 10 ml.

Assay of B₁₂. [⁵⁷Co]B₁₂ (Amersham-Searle Corp., Arlington Heights, Ill., 150-200 μCi/μg) was diluted with nonradioactive crystalline B₁₂ (Sigma Chemical Corp., St. Louis, Mo.) to achieve specific activities of 20-40 μCi/μg.

Items containing [⁵⁷Co]B₁₂ were assayed by measuring radioactivity in a Packard γ scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill.). Solutions of crystalline B₁₂ dissolved in water were assayed by measuring the absorbance at 361 nm and 550 nm. Molar extinction coefficients of E_{1 cm} 361 = 27,700 and E_{1 cm} 550 = 8,680 were used (20). The values for B₁₂ concentration obtained at each wave length always agreed within 5%, and the average value was used. The endogenous B₁₂ content of ileal homogenates was assayed by the isotope dilution technique of Lau, Gottlieb, Wasserman, and Herbert (21).

Assay of B₁₂-binding activity. B₁₂-binding activity was assayed by a modification (22) of the charcoal adsorption technique of Gottlieb, Lau, Wasserman, and Herbert (23).

Gel filtration. Preparation and calibration of columns of Sephadex G-150, fine grade, were performed as described previously (22).

Preparation of B₁₂-binding proteins. Human IF (22), hog IF (24), hog NIF (24), human plasma transcobalamin II (25), human granulocyte B₁₂-binding protein (26), human milk B₁₂-binding protein,² and human salivary B₁₂-binding protein² were purified as previously described. All preparations were homogeneous when measured by polyacrylamide gel electrophoresis and sedimentation equilibrium ultracentrifugation. Greater than 98% of the B₁₂-binding activity present in the preparations of human IF and hog IF employed was inhibited by anti-IF antibody obtained from the serum of a patient with pernicious anemia (22). The preparations of human IF and hog IF employed also were active in vivo based on Schilling tests (22, 24).

Saturation of B₁₂-binding proteins with [⁵⁷Co]B₁₂. A threefold excess (based on B₁₂-binding activity) of [⁵⁷Co]-B₁₂ (20-40 μCi/μg B₁₂) was added to individual B₁₂-binding proteins (1-3 μg protein/ml) in 7.5 M guanidine-HCl containing 0.1 M potassium phosphate, pH 7.5. Proteins were dialyzed subsequently for 72 h at 4°C against 2,000 vol of 0.05 M potassium phosphate, pH 7.5, containing 0.75 M NaCl, with dialysate changes at 24 and 48 h. Greater than 99% of unbound B₁₂ was removed under these conditions. Protein preparations devoid of B₁₂ were prepared in the same manner except that B₁₂ was not added before dialysis. Dialyzed protein preparations were stored at -20°C. B₁₂-binding proteins were diluted in KRPO₄-Ca⁺⁺/Mg⁺⁺ before being used for intestinal mucosal binding studies.

Assay of B₁₂-binding to intestinal mucosal homogenates. Incubations were performed in 10-mm × 75-mm glass test tubes presoaked for 2 h before use in a solution of bovine serum albumin, 1 mg/ml in distilled water. The tubes were aspirated to dryness subsequently with a vacuum aspirator. Millipore filters (Millipore Corp., Bedford, Mass.) (1.2 μm mean pore size-RA 02500) were presoaked in the same bovine serum albumin solution for 4 h before use.

Standard incubation mixtures contained the following components in order of addition: first, 0.72 ml of KRPO₄; second, 0.2 ml of intestinal mucosal homogenate suspended in KRPO₄-Ca⁺⁺/Mg⁺⁺; and third, 0.08 ml of the solution containing free [⁵⁷Co]B₁₂ or [⁵⁷Co]B₁₂ bound to protein. This solution contained three parts 0.05 M potassium phosphate, pH 7.5, 0.75 M NaCl, and eight parts KRPO₄-Ca⁺⁺/Mg⁺⁺. Incubation mixtures were prepared at 4°C and placed in a 22°C water bath for 5 min before the addition of [⁵⁷Co]B₁₂. After standing at 22°C for an additional 180-210 min, the intestinal mucosal homogenates were col-

² Burger, R. L., and R. H. Allen. Manuscript in preparation.




FIGURE 1 Time course of EDTA-inhibitable B₁₂ binding to guinea pig ileal mucosal homogenate. The concentration of B₁₂ in the standard incubation medium was 100 pg/ml. ■, free B₁₂; □, hog NIF-B₁₂; ○, hog IF-B₁₂; ●, human IF-B₁₂.

lected on Millipore filters by vacuum filtration. Assay tubes and filters were rinsed three times with 4 ml of incubation solution, and the filters were assayed directly for [⁵⁷Co]B₁₂ in a Packard γ scintillation counter. Assays were performed in duplicate, and the average value was used. Duplicates varied by less than 10%. In most experiments, duplicate assays were also performed in which KRPO₄ was replaced with KRPO₄ - Ca⁺⁺/Mg⁺⁺ + 0.001 M Na₂ EDTA (KRPO₄ - Ca⁺⁺/Mg⁺⁺ + EDTA). The difference between B₁₂ bound to intestinal mucosal homogenates in KRPO₄ and KRPO₄ - Ca⁺⁺/Mg⁺⁺ + EDTA was termed the "EDTA-inhibitable" fraction.

Determination of binding constants. The association constant, K_a for the binding of IF-B₁₂ to ileal mucosal homogenate binding sites is defined as

$$K_a = \frac{[\text{IF-B}_{12}]_{\text{bound}}}{[\text{ileal IF-B}_{12} \text{ binding site}]_{\text{free}} [\text{IF-B}_{12}]_{\text{free}}}$$

TABLE I
Characterization of IF-B₁₂ Binding to Ileal Mucosal Homogenates

Assay conditions	[⁵⁷ Co]B ₁₂ bound to ileal mucosal homogenates					
	Human IF-B ₁₂			Hog IF-B ₁₂		
	guinea pig*	human*	hog*	guinea pig*	human*	hog*
	pg	pg	pg	pg	pg	pg
Standard†	23.0	16.6	13.6	22.7	16.1	17.4
+0.001 M Na ₂ EDTA	23.1	16.5	13.4	22.9	16.2	17.1
-Ca ⁺⁺ , -Mg ⁺⁺	17.1	16.5	13.1	16.7	15.8	17.3
-Ca ⁺⁺ , -Mg ⁺⁺ , +0.001 M Na ₂ EDTA	0.4	0.5	1.3	0.8	1.3	1.3
+Normal serum§	22.8	16.8	13.7	22.4	16.3	17.0
+Anti-IF antibody serum§	1.0	1.6	0.8	0.9	1.4	1.2
-Ileal homogenate	0.2	0.2	0.2	0.2	0.2	0.2
-Ileal homogenate +Jejunal homogenate	0.4	0.7	1.7	0.8	0.9	1.3

* Homogenate species.

† Assays contained 0.72 ml of KRPO₄; 0.08 ml containing 100 pg of [⁵⁷Co]B₁₂ in a solution consisting of eight parts KRPO₄ - Ca⁺⁺/Mg⁺⁺ and three parts 0.05 M potassium phosphate, 0.75 M NaCl; and 0.2 ml of ileal mucosal homogenate.

§ 0.2 ml of serum was added in place 0.2 ml of KRPO₄.

where [IF-B₁₂]_{bound} is the concentration of IF-B₁₂ bound to ileal IF-B₁₂-binding sites, [ileal IF-B₁₂-binding site]_{free} is the concentration of ileal IF-B₁₂-binding sites unoccupied by IF-B₁₂, and where [IF-B₁₂]_{free} is the concentration of IF-B₁₂ free in solution. Defined in this way, the total number of ileal IF-B₁₂-binding sites is equal to [IF-B₁₂]_{bound} + [ileal IF-B₁₂-binding site]_{free}. Data from ileal mucosal homogenate binding studies, performed with varying amounts of human IF-B₁₂ and hog IF-B₁₂, were obtained, and the method of Steck and Wallach (27) was used to calculate the value for K_a and for the total number of ileal mucosal homogenate binding sites.

Precipitation of IF-B₁₂ with anti-IF antibody. Sera from pernicious anemia patients were assayed for binding antibodies to human IF-B₁₂ by a modification of the method of Rothenberg and Huhti (15). Test tubes containing 0.5 ml of serum consisting of varying amounts of normal and antibody-positive sera and 1.0 ml of 0.075 M potassium phosphate, pH 7.5, 0.375 M NaCl, and 100 pg of [⁵⁷Co]B₁₂ bound to human IF were incubated at 22°C for 30 min. The tubes were then placed in an ice bath and 1.5 ml of cold 30% Na₂SO₄ was added. After standing for an additional 10 min, the tubes were centrifuged at 20,000g for 10 min and 1 ml of supernatant solution was removed and assayed for [⁵⁷Co]B₁₂.

RESULTS

General properties of ileal IF-B₁₂ binding. The properties of homogeneous human and hog IF-B₁₂ binding to guinea pig, human, and hog ileal mucosal homogenates are illustrated in Table I. Under standard conditions at a B₁₂ concentration of 100 pg/ml, 13.6%-23.0% of human IF-B₁₂ and 16.1%-22.7% of hog IF-B₁₂ were bound to these ileal mucosal homogenates. When the standard incubation medium contained 0.001 M Na₂-EDTA, there was no effect on binding. When Ca⁺⁺ and Mg⁺⁺ were omitted from the incubation medium, there was no effect

on human IF-B₁₂ and hog IF-B₁₂ binding to human and hog ileal mucosal homogenates and only a slight but reproducible inhibition of binding to guinea pig ileal mucosal homogenate. When 0.001 M Na₂-EDTA was present in Ca⁺⁺- and Mg⁺⁺-free incubation medium, there was greater than 90% inhibition of human IF-B₁₂ and hog IF-B₁₂ binding to the ileal mucosal homogenates of all three species. Marked inhibition of IF-B₁₂ binding to ileal mucosal homogenates was also observed in the presence of serum containing antibodies to the IF-B₁₂ complex, and when the ileal mucosal homogenate was either omitted from the incubation system or replaced with jejunal mucosal homogenate. Similar small amounts of IF-B₁₂ binding were observed when these last experiments were performed in the presence of 0.001 M Na₂-EDTA in standard medium lacking added Ca⁺⁺ and Mg⁺⁺ (data not shown).

Protein specificity. The results of experiments performed to determine the ileal mucosal homogenate binding of 100 pg/ml B₁₂, present in either free form or bound to each of seven different homogeneous B₁₂-binding proteins, are presented in Table II. Under standard incubation conditions, B₁₂ bound to human IF and hog IF was bound to ileal mucosal homogenates in significantly greater amounts than was free B₁₂ or B₁₂ bound to hog NIF, human transcobalamin II, or human milk, salivary, and granulocyte B₁₂-binding proteins. It is also important to note that ileal mucosal homogenate B₁₂ binding was inhibited significantly by 0.001 M EDTA in the absence of added Ca⁺⁺ and Mg⁺⁺ only in the cases of human IF-B₁₂ and hog IF-B₁₂.

Time-course of ileal IF-B₁₂ binding. The time-course of EDTA-inhibitable B₁₂ binding to guinea pig ileal mucosal homogenates is presented in Fig. 1. B₁₂ binding




FIGURE 2 Effect of pH on EDTA-inhibitable B₁₂ binding to guinea pig ileal mucosal homogenate. Potassium phosphate was omitted from the standard incubation medium, which was adjusted to contain 0.015 N acetic acid, 0.015 M tricine, 0.015 M glycine, and sufficient NaOH to achieve the desired pH value. These changes were required to avoid precipitates of calcium and phosphate at pH values above 8 as well as to obtain sufficient buffer capacity from pH 4 to pH 11. The B₁₂ concentration in the incubation medium was 100 pg/ml. The incubation period was 180 min. Δ , free B₁₂; \square , hog NIF-B₁₂; \circ , hog IF-B₁₂; \bullet , human IF-B₁₂.

reaches a maximum with human IF-B₁₂ and hog IF-B₁₂ at 150–210 min. Similar rates of binding were observed with ileal mucosal homogenates of all other species (data not shown). These findings led to our choice of 180–210 min incubations for the standard assay. Only negligible EDTA-inhibitable binding of free B₁₂ or hog NIF-B₁₂ occurs over the entire incubation period.

pH dependence of ileal IF-B₁₂ binding. The pH dependence of EDTA-inhibitable B₁₂ binding to guinea pig

TABLE II
Effect of Homogeneous B₁₂ Binding Proteins on B₁₂ Binding to Ileal Mucosal Homogenates

B ₁₂ binding protein present	[⁵⁷ Co]B ₁₂ bound to ileal mucosal homogenates								
	Guinea pig homogenate			Human homogenate			Hog homogenate		
	(1)	(2)	(1)-(2)	(1)	(2)	(1)-(2)	(1)	(2)	(1)-(2)
	standard*	-Ca ⁺⁺ , -Mg ⁺⁺ , +0.001 M Na ₂ -EDTA*	EDTA-inhibitable	standard*	-Ca ⁺⁺ , -Mg ⁺⁺ , +0.001 M Na ₂ -EDTA*	EDTA-inhibitable	standard*	-Ca ⁺⁺ , -Mg ⁺⁺ , +0.001 M Na ₂ -EDTA*	EDTA-inhibitable
None	pg	pg	pg	pg	pg	pg	pg	pg	pg
Human IF	23.1	0.4	22.7	16.6	0.5	16.1	13.6	1.0	12.6
Hog IF	22.7	0.8	21.9	16.1	1.3	14.8	17.4	1.3	16.1
Hog NIF	1.5	1.0	0.5	2.4	2.5	0.1	3.6	3.2	0.4
Human transcobalamin II	1.8	2.6	-0.8	1.4	1.6	-0.2	8.6	7.5	1.1
Human milk B ₁₂ binder	0.0	0.0	-0.0	0.3	0.0	0.3	0.2	0.0	0.2
Human salivary B ₁₂ binder	0.2	0.1	0.1	0.5	0.5	0.0	0.1	0.4	-0.3
Human granulocyte B ₁₂ binder	0.6	0.4	0.2	0.5	0.4	0.1	1.1	0.8	0.3

All assays were performed at a concentration of [⁵⁷Co]B₁₂ of 100 pg/ml.

* Assay medium.




FIGURE 3 Time course of human IF-B₁₂ release from guinea pig ileal mucosal homogenate. Human IF-B₁₂ (100 pg [⁵⁷Co]-B₁₂/ml) was incubated for 180 min at 22°C in 1.0 ml of standard (KRPO₄) incubation medium containing guinea pig ileal mucosal homogenate. Individual assay tubes were centrifuged subsequently and the pellets were washed three times in standard incubation medium. The final pellets were incubated in 4.0 ml of reincubation medium for various time periods at 22°C, collected on Millipore filters, and assayed for [⁵⁷Co]B₁₂. The reincubation media consisted of ●, KRPO₄ (pH 7.4); ○, KRPO₄ - Ca⁺⁺/Mg⁺⁺ + EDTA (pH 7.4); and △, KRPO₄ - Ca⁺⁺/Mg⁺⁺ containing 0.001 N citric acid and sufficient HCl to adjust the pH to 5.0. Based on the k_a ($13.0 \times 10^6 \text{ M}^{-1}$) for IF-B₁₂ and this ileal homogenate preparation, and on the number of ileal binding sites (1.2×10^{12} g wet wt) determined for this homogenate preparation (see below), the expected amount of IF-B₁₂ bound to ileal binding sites at equilibrium after reincubation in standard medium was calculated to be 2.0 pg.

ileal mucosal homogenates is demonstrated in Fig. 2. Below pH 5.6 and above pH 10.5 IF-mediated B₁₂ binding is minimal, and negligible free B₁₂ or hog NIF-B₁₂ binding occurs from pH 5.0 to pH 11.5. Optimal IF-mediated B₁₂ binding occurs between pH 6.5 and pH 9.5. Similar curves were observed with hog and human ileal mucosal homogenates.

Saturability and specificity of ileal IF-B₁₂ binding. To study the saturability and specificity of EDTA-inhibitable IF-B₁₂ binding to ileal mucosal homogenates, 100-fold excesses of nonradioactive human IF-B₁₂, hog IF-B₁₂, hog NIF-B₁₂, free B₁₂, and human IF, hog IF, and hog NIF devoid of B₁₂ were added to standard assay mixtures containing 100 pg of [⁵⁷Co]B₁₂ bound to human or hog IF. The results are presented in Table III and demonstrate that a limited number of binding sites for

human IF-B₁₂ and hog IF-B₁₂ exists, because 100-fold excesses of nonradioactive human and hog IF-B₁₂ cause greater than 90% inhibition of IF-[⁵⁷Co]B₁₂ binding to ileal mucosal homogenates. The finding that nonradioactive human IF-B₁₂ inhibits hog IF-[⁵⁷Co]B₁₂ binding to ileal mucosal homogenates, and that nonradioactive hog IF-B₁₂ inhibits human IF-[⁵⁷Co]B₁₂ binding to ileal mucosal homogenates also suggests that human IF-B₁₂ and hog IF-B₁₂ bind to the same ileal mucosal homogenate binding sites. The finding that 100-fold excesses of nonradioactive free B₁₂ and hog NIF-B₁₂ cause no detectable inhibition of either human IF-[⁵⁷Co]B₁₂ or hog IF-[⁵⁷Co]B₁₂ ileal mucosal homogenate binding indicates that free B₁₂ and hog NIF-B₁₂ have affinities for ileal mucosal IF-B₁₂-binding sites that are at least three orders of magnitude lower than that of human IF-B₁₂ and hog IF-B₁₂. Data in Table III also support similar conclusions about the maximal possible affinities of human IF and hog IF devoid of B₁₂ for human and hog ileal mucosal homogenate IF-B₁₂-binding sites. A reproducible 20% inhibition of human IF-[⁵⁷Co]B₁₂ and hog IF-[⁵⁷Co]B₁₂ binding to guinea pig ileal mucosal homogenates was effected by 100-fold excesses of human and hog IF devoid of B₁₂, suggesting that they may have definite affinities for guinea pig ileal mucosal homogenate IF-B₁₂-binding sites, although such affinities appear to be approximately 2½ orders of magnitude lower than those of human IF-B₁₂ and hog IF-B₁₂. This degree of inhibition is also compatible, however, with the presence of small amounts, i.e. approximately 25 pg, of free endogenous B₁₂ in the guinea pig homogenate. This possibility is supported by the fact that 0.2 ml of washed guinea pig ileal mucosal homogenate contains approximately 500 pg of endogenous B₁₂. Human and hog ileal mucosal homogenates contained 50 and 30 pg B₁₂/0.200 ml, respectively. The amount of this endogenous B₁₂ that becomes free during the incubation period has not been determined.

Release of IF-B₁₂ from ileal mucosal homogenate. The results of experiments performed to determine the rate of release of human IF-B₁₂ bound to guinea pig ileal mucosal homogenate are presented in Fig. 3 and indicate that IF-B₁₂ is released slowly under standard assay conditions with a t_1 of release of greater than 18 h. Fig. 3 also demonstrates that release is faster in a medium devoid of Ca⁺⁺ and Mg⁺⁺ and containing EDTA (t_1 = 40–60 min) and even more rapid at pH 5.0 (t_1 = 5–10 min). Similar results were obtained when the release of hog IF-B₁₂ was studied.

Reversibility of ileal IF-B₁₂ binding. The results of a large-scale experiment performed to obtain B₁₂ released from ileal mucosal homogenate are presented in Table IV. When the B₁₂ released from the guinea pig ileal mucosal homogenate at pH 5.0 with EDTA was dialyzed at

TABLE III
Specificity and Saturability of EDTA-Inhibitable IF-B₁₂ Binding to Ileal Mucosal Homogenates

Nonradioactive item present in 100-fold excess	[⁵⁷ Co]B ₁₂ bound to ileal mucosal homogenates					
	Human IF-B ₁₂			Hog IF-B ₁₂		
	guinea pig*	human*	hog*	guinea pig*	human*	hog*
None	pg 13.8	pg 12.0	pg 12.5	pg 13.4	pg 12.9	pg 10.0
Human IF + B ₁₂	0.7	0.6	0.0	0.6	0.4	0.4
Hog IF + B ₁₂	0.3	0.2	0.4	0.8	0.6	0.9
Hog NIF + B ₁₂	13.5	11.8	12.3	13.1	12.7	10.3
Free B ₁₂	14.3	12.0	12.0	14.4	12.7	10.0
Human IF	12.5	12.9	12.6	11.2	14.1	10.2
Hog IF	11.4	12.3	11.3	10.1	12.4	10.0

* Homogenate species.

Assays were performed at a concentration of [⁵⁷Co]B₁₂ of 100 pg/ml. Standard assay conditions were employed as described in Methods except that ileal mucosal homogenate was the last item added to incubation mixtures.

4°C for 24 h against 40 vol of 0.05 M potassium phosphate, pH 7.5, containing 0.75 M NaCl, less than 10% of the B₁₂ was recovered in the dialysate, according to measurements of radioactivity. This observation suggested that the B₁₂ released from ileal mucosal homogenate was bound to a macromolecule. This was confirmed by the observation that the dialyzed, released B₁₂ eluted from Sephadex G-150 with an apparent molecular weight of 65,000, the same as the apparent molecular weight of human IF-B₁₂ under these conditions (22). The released and dialyzed B₁₂ was bound to guinea pig ileal homogenate in an amount comparable to that of human IF-B₁₂, and this observation, together with the finding that released B₁₂ is precipitated with anti-IF antibody in 15% Na₂SO₄ in a manner equivalent to human IF-B₁₂, demonstrates that the human IF-B₁₂ complex is bound to guinea pig ileal mucosal homogenate under our standard assay conditions and that this binding is reversible.

Binding constants and species specificity of ileal IF-B₁₂ binding. The amounts of EDTA-inhibitable IF-B₁₂ binding to ileal mucosal homogenates at varying concentrations of IF-B₁₂ were used to calculate association constants for human and hog IF-B₁₂ and guinea pig, human, and hog ileal mucosal homogenates as presented in Fig. 4. The concentration of IF-B₁₂ bound to the ileal mucosal homogenates, [IF-B₁₂]_{bound}, was calculated under the assumption that each ileal mucosal homogenate binding site binds one molecule of IF-B₁₂. The concentration of IF-B₁₂ remaining free in solution, [IF-B₁₂]_{free}, was calculated by subtracting [IF-B₁₂]_{bound} from the total concentration of IF-B₁₂ present in the incubation mixture. We have demonstrated (22, 24) that human IF and hog IF both contain single B₁₂-binding sites, but it is important to note that our calculation of [IF-B₁₂]_{free} does

assume that under our standard assay conditions IF-B₁₂ does not aggregate to form a series of oligomers, as can occur (22, 24). This assumption is supported by the finding that when human IF-B₁₂ (100 pg B₁₂/ml) was incubated at 22°C for 180 min in standard assay medium and then placed on a 2.0 × 60-cm column of Sephadex G-150 equilibrated at 22°C with standard assay medium, more than 90% of IF-B₁₂ eluted with an apparent molecular weight of 65,000, i.e. the apparent monomeric molecu-

TABLE IV
Release of [⁵⁷Co]B₁₂ from Guinea Pig Ileal Mucosal Homogenate Incubated Previously with Human IF-[⁵⁷Co]B₁₂

Item	Volume	[⁵⁷ Co]B ₁₂	
		ml	pg %
Incubation mixture in KRPO ₄	200		20,000 100.0
Supernate after centrifugation			
1. Initial	190	11,700	58.5
2. 1st wash in KRPO ₄	200	660	3.3
3. 2nd wash in KRPO ₄	200	360	1.8
4. 3rd wash in KRPO ₄	200	330	1.6
5. After suspension in pH 5.0 KRPO ₄ - Ca ⁺⁺ /Mg ⁺⁺ + EDTA containing 0.001 N citric acid	27.5	5,900	29.5
Final pellet		460	2.3
Supernate 5 after dialysis at 4°C against 1.0 liter, of 0.05 M potassium phosphate pH 7.5, 0.75 M NaCl	26.0	5,510	27.6

A standard incubation mixture was prepared in 200 ml of KRPO₄ medium containing 40 ml of guinea pig ileal mucosal homogenate and 20000 pg of [⁵⁷Co]B₁₂ bound to human IF. After an incubation period of 180 min at 22°C, the mixture was centrifuged at 10,000g and the pellet washed three times in KRPO₄ medium and suspended for 15 min in pH 5.0 KRPO₄ - Ca⁺⁺/Mg⁺⁺ + EDTA containing 0.001 N citric acid. The suspension was then recentrifuged.




FIGURE 4 Double reciprocal plots of EDTA-inhibitable IF-B₁₂ binding to ileal mucosal homogenates versus IF-B₁₂ concentration. Values for K_d and the number of IF-B₁₂ binding sites/0.2 ml of ileal mucosal homogenate were determined as described in Methods. A, guinea pig ileal mucosal homogenate; B, human ileal mucosal homogenate; C, hog ileal mucosal homogenate.

lar weight of human IF-B₁₂ (22). A similar result was obtained when human IF-B₁₂ was incubated and chromatographed on Sephadex G-150 in medium containing $\text{KRPO}_4 - \text{Ca}^{++}/\text{Mg}^{++} + \text{EDTA}$.

EDTA-inhibitable binding of human IF-B₁₂ and hog IF-B₁₂ to intestinal mucosal homogenates prepared from rabbits, hamsters, dogs, mice, and monkeys was also observed. The specificity and saturability of ileal IF-B₁₂ binding in each species was demonstrated by the findings that (a) EDTA-inhibitable IF-B₁₂ binding was limited

to ileal mucosal homogenates and was not observed with jejunal mucosal homogenates; (b) more than 90% of EDTA-inhibitable IF-B₁₂ binding was inhibited by a 100-fold excess of nonradioactive IF-B₁₂; (c) more than 90% of EDTA-inhibitable IF-B₁₂ binding was inhibited with anti-IF antibody; (d) no EDTA-inhibitable binding of free B₁₂ or hog NIF-B₁₂ was observed; and (e) plots of $1/[\text{IF-B}_{12}]_{\text{bound}}$ vs $1/[\text{IF-B}_{12}]_{\text{free}}$ were linear. EDTA-inhibitable IF-B₁₂ binding was not observed in proximal, mid, or distal mucosal homogenates from rat or bovine small intestine.

The data obtained from all of the species tested are presented in Table V. Values for K_d for human and hog IF-B₁₂, and different ileal mucosal homogenate preparations from the same species differed by as much as 50%, but the relative differences observed for the K_d for human IF-B₁₂ and hog IF-B₁₂ varied by less than 10%. Human IF-B₁₂ appears to have a slightly greater affinity for human, monkey, and dog ileal mucosal IF-B₁₂-binding sites than does hog IF-B₁₂. The reverse appears true in the case of hog, and especially hamster and mouse ileal IF-B₁₂-binding sites. No significant differences between the number of human IF-B₁₂-binding sites and the number of hog IF-B₁₂-binding sites were observed in any individual ileal mucosal homogenate preparation, a finding consistent with our observation (see above) that human IF-B₁₂ and hog IF-B₁₂ bind to the same binding sites.

DISCUSSION

B₁₂ bound to human and hog IF is bound to ileal mucosal homogenates in a number of different species in significantly greater amounts than is free B₁₂, or B₁₂ bound to

TABLE V
Species Specificity of EDTA-Inhibitable IF-B₁₂ Binding to Ileal Mucosal Homogenates

Ileal homogenate	K_d		Number of binding sites per wet weight of ileal mucosa	
	Human IF-B ₁₂	Hog IF-B ₁₂	Human IF-B ₁₂	Hog IF-B ₁₂
Species	10^9 M^{-1}	10^9 M^{-1}	$10^{12}/\text{g}$	$10^{12}/\text{g}$
Guinea pig	13.0	13.0	1.2	1.2
Guinea pig	9.5	9.3	0.9	0.9
Rabbit	3.4	3.1	0.4	0.5
Human	4.1	3.4	2.5	2.6
Human	3.4	2.7	0.4	0.5
Human	5.6	5.0	0.4	0.4
Monkey	5.9	5.0	0.4	0.4
Dog	6.6	4.3	4.8	4.7
Hog	0.9	1.3	4.7	4.9
Hamster	0.4	1.1	1.8	1.6
Mouse	0.3	1.1	0.3	0.3
Rat	<0.1	<0.1	—	—
Bovine	<0.1	<0.1	—	—

Each set of determinations was performed with a different preparation of ileal mucosal homogenate. Values for human IF-B₁₂ and hog IF-B₁₂ were obtained simultaneously with each ileal mucosal homogenate preparation.

hog NIF, human transcobalamin II, or B₁₂-binding proteins isolated from human milk, saliva, and granulocytes. Since these observations were made with homogeneous protein preparations, the observed differences in ileal B₁₂ binding are due to structural differences in the individual B₁₂-binding proteins rather than to the presence of inhibitors or stimulators of ileal B₁₂ binding that might exist in the crude tissue extracts or body fluids in which these proteins are found. The physiologic significance of the relatively small amounts of B₁₂ binding to ileal mucosal homogenates observed with free B₁₂ and with B₁₂ bound to the B₁₂-binding proteins other than IF is not known. This type of binding appears to be different from IF-B₁₂ ileal binding, however, in that it is not inhibited by EDTA, low pH, or anti-IF antibody and is not localized to the distal portion of the small intestine.

Our studies also indicate that gastric factors other than IF are not required during the actual process of IF-B₁₂ binding to ileal binding sites, since homogeneous human and hog IF are able to facilitate B₁₂ binding to ileal mucosal homogenates of the same order of magnitude that other investigators have observed with whole gastric juice in similar assays (4, 7-10). Gastric factors may exist that alter the IF molecule after its synthesis in the gastric mucosa, but if such factors do exist, their action must have occurred before our isolation of human and hog IF.

In previous studies, in which crude gastric juice was employed as the source of IF, some (2, 7, 9, 11, 14, 15) but not all (6, 8, 16) investigators have observed decreases in ileal B₁₂ binding when increasing amounts of gastric juice, containing unsaturated B₁₂-binding activity, were added to their assay systems. The former observations have suggested that IF devoid of B₁₂ might have an appreciable affinity for the ileal IF-B₁₂-binding site and thus be the cause of the inhibition of ileal IF-B₁₂ binding. Other interpretations are available, however, and include the possibility that crude gastric juice contains substances other than IF that inhibit ileal IF-B₁₂ binding. This possibility is suggested by the fact that Donaldson, Mackenzie, and Trier (11) observed that partially purified hamster IF-B₁₂ was bound to hamster ileal brush borders in significantly greater amount than was unpurified hamster IF-B₁₂. We have not examined IF from all of the species utilized in the studies mentioned above, but our studies employing homogeneous human and hog IF indicate that these two proteins, devoid of B₁₂, have relatively low, if any, affinity for guinea pig, human, and hog ileal IF-B₁₂-binding sites. This suggests that the ileal IF-B₁₂-binding site either interacts with portions of both the B₁₂ and IF molecules or that B₁₂ binding to IF results in important conformational changes in that portion of the B₁₂ and/or IF molecule that interacts with the ileal binding site. It is

possible that the structures of human and hog IF are altered during their purification and that such alterations are responsible for their failure to bind significantly to ileal IF-B₁₂-binding sites in the absence of B₁₂. This type of alteration could have occurred when the proteins were exposed to high concentrations of guanidine-HCl during their purification but appears unlikely since human IF and hog IF can be renatured from 7.5 M guanidine-HCl in the absence of B₁₂ with full preservation of their abilities to bind B₁₂, and facilitate B₁₂ absorption as judged by Schilling tests (22, 24).

Human gastric juice and crude preparations of hog gastric mucosa contain B₁₂-binding proteins that lack IF activity, as judged by Schilling tests (17, 24, 28, 29). These proteins have been referred to as human gastric R binder and hog NIF. The source of human gastric R binder is not entirely clear, but recent studies (22) suggest that most, if not all, of this B₁₂ binding protein may result from the contamination of gastric juice with saliva. We have recently isolated the human salivary B₁₂-binding protein² and hog NIF (24), and have shown that they differ from human and hog IF immunologically as well as in terms of molecular weight and amino acid and carbohydrate composition. The studies presented here indicate that neither the salivary protein nor hog NIF are able to facilitate B₁₂ binding to ileal IF-B₁₂-binding sites. This observation, together with the fact that these proteins are present in gastric preparations in variable amounts relative to IF (7, 23, 30), may explain some of the conflicting data in the literature about the relative ability of human IF and hog IF to facilitate ileal B₁₂ binding (1, 2, 10, 18, 31) and absorption (18, 19) in various species.

Human IF and hog IF both facilitate B₁₂ binding to human, dog, monkey, hog, hamster, mouse, guinea pig, and rabbit intestine mucosal homogenates with affinities that range from $0.3 \times 10^6 \text{ M}^{-1}$ to $13 \times 10^6 \text{ M}^{-1}$. Both IF-B₁₂ complexes have similar affinities for guinea pig and rabbit ileal IF-B₁₂-binding sites, but differences in affinity appear to exist with respect to the other six ileal mucosal homogenates. These differences indicate that human IF and hog IF have different structures. This observation is consistent with our recent experiments (22, 24) demonstrating that human IF and hog IF do differ slightly, but significantly, in amino acid and carbohydrate composition, molecular weight, and in their interaction with anti-IF antibody and pseudo-B₁₂ (α -adenyl cobamide cyanide).

Uncertainty exists about the fate of the IF-B₁₂ complex after its attachment to the ileal mucosal IF-B₁₂ binding site, but at some point B₁₂ must be dissociated from IF since IF does not appear to enter the portal circulation with B₁₂ (32, 33). The factor, or factors, responsible for this dissociation are undefined, but it is

possible that species specificity exists in this process and that this specificity may well differ from that involved in IF-B₁₂ binding to ileal IF-B₁₂-binding sites. Because of this possibility, it is important to note that the demonstration that human IF-B₁₂ binds to a particular species of ileal IF-B₁₂-binding site does not demonstrate that human IF-B₁₂ is capable of facilitating actual B₁₂ absorption in that species.

One additional point of caution about the interpretation of our results is that little is known about the fate of the IF-B₁₂ complex during its passage from the stomach to the distal small intestine. During the passage the IF-B₁₂ complex is exposed to a large number of gastric, pancreatic, and intestinal proteolytic enzymes, glycosidases, and other factors that could alter the structure of the IF-B₁₂ complex before it binds to the ileal IF-B₁₂-binding site. This consideration is important since it suggests that under physiological *in vivo* conditions, IF-B₁₂ binding to ileal IF-B₁₂-binding sites might be different from that observed with homogeneous IF isolated from gastric juice and gastric mucosa. Other recent studies (34-36), demonstrating B₁₂ malabsorption in humans and rats with pancreatic insufficiency and its correction with pancreatic extracts and highly purified preparations of trypsin, suggest that differences might exist between *in vivo* and *in vitro* ileal IF-B₁₂ binding.

ACKNOWLEDGMENTS

This investigation was supported by Research grants AM 16668, HE 00022, AM 14038, AM 05280, and Special Research Fellowship AM 51261 from the National Institutes of Health.

REFERENCES

1. Wilson, T. H., and E. W. Strauss. 1959. Some species differences in the intrinsic factor stimulation of B₁₂ uptake by small intestine *in vitro*. *Am. J. Physiol.* **197**: 926.
2. Herbert, V. 1959. Mechanism of intrinsic factor action in everted sacs of rat small intestine. *J. Clin. Invest.* **38**: 102.
3. Strauss, E. W., and T. H. Wilson. 1960. Factors controlling B₁₂ uptake by intestinal sacs *in vitro*. *Am. J. Physiol.* **198**: 103.
4. Herbert, V., and W. B. Castle. 1961. Divalent cations and pH dependence of rat intrinsic factor action in everted sacs and mucosal homogenates of rat small intestine. *J. Clin. Invest.* **40**: 1978.
5. Cooper, B. A., W. Paranchych, and L. Lowenstein. 1962. Studies on the absorption by guinea pig intestine of cyanocobalamin incubated with intrinsic factor. *J. Clin. Invest.* **41**: 370.
6. Cooper, B. A. 1964. The uptake of ⁵⁷Co-labeled vitamin B₁₂ by everted sacs of intestine *in vitro*. *Medicine (Baltimore)*. **43**: 689.
7. Sullivan, L. W., V. Herbert, and W. B. Castle. 1963. *In vitro* assay for human intrinsic factor. *J. Clin. Invest.* **42**: 1443.
8. Rosenberg, A. H., K-S. Lau, and V. Herbert. 1965. Enhancement by intrinsic factor (IF) of vitamin B₁₂ uptake by human ileal homogenate. *Clin. Res.* **13**: 281.
9. England, J. M., and K. B. Taylor. 1966. The action of rat gastric juice upon the uptake of ⁵⁸Co B₁₂ by guinea pig intestinal mucosal homogenate. *Clin. Res.* **14**: 135.
10. Carmel, R., A. H. Rosenberg, K-S. Lau, R. R. Streiff, and V. Herbert. 1969. Vitamin B₁₂ uptake by human small bowel homogenate and its enhancement by intrinsic factor. *Gastroenterology*. **56**: 548.
11. Donaldson, R. M., Jr., I. L. Mackenzie, and J. S. Trier. 1967. Intrinsic factor-mediated attachment of vitamin B₁₂ to brush borders and microvillous membranes of hamster intestine. *J. Clin. Invest.* **46**: 1215.
12. Mackenzie, I. L., and R. M. Donaldson, Jr. 1972. Effect of divalent cations and pH on intrinsic factor-mediated attachment of vitamin B₁₂ to intestinal microvillous membranes. *J. Clin. Invest.* **51**: 2465.
13. Katz, M., and B. A. Cooper. 1972. A soluble receptor for intrinsic factor-B₁₂ from human ileum. *Blood J. Hematol.* **40**: 960.
14. Boass, A., and T. H. Wilson. 1963. An assay for gastric intrinsic factor. *Am. J. Physiol.* **204**: 97.
15. Rothenberg, S. P., and A. L. Huhti. 1968. Identification of a macromolecular factor in the ileum which binds intrinsic factor and immunologic identification of intrinsic factor in ileal extracts. *J. Clin. Invest.* **47**: 913.
16. Ukyo, S., and B. A. Cooper. 1965. Intrinsic factor-like activity in extracts of guinea pig intestine. *Am. J. Physiol.* **208**: 9.
17. Gräsbeck, R. 1969. Intrinsic factor and the other vitamin B₁₂ transport proteins. *Prog. Hematol.* **6**: 233.
18. Holdsworth, E. S., and M. E. Coates. 1960. The absorption of vitamin B₁₂ in animals. I. The effect of different binding and intrinsic factors. *Clin. Chim. Acta.* **5**: 853.
19. Hippe, E., and M. Schwartz. 1971. Intrinsic factor activity of stomach preparations from various animal species. *Scand J. Haematol.* **8**: 276.
20. The Merck Index. 1968. Stecher, P. G., editor. Merck and Company, Rahway, N. J. 8th edition. 1112.
21. Lau, K-S., C. Gottlieb, L. R. Wasserman, and V. Herbert. 1965. Measurement of serum vitamin B₁₂ level using radioisotope dilution and coated charcoal. *Blood J. Hematol.* **26**: 202.
22. Allen, R. H., and C. S. Mehlman. 1973. Isolation of gastric vitamin B₁₂ binding proteins using affinity chromatography. I. Purification and properties of human intrinsic factor. *J. Biol. Chem.* **248**: 3660.
23. Gottlieb, C., K-S. Lau, L. Wasserman, and V. Herbert. 1965. Rapid charcoal assay for intrinsic factor (IF), gastric juice unsaturated B₁₂ binding capacity, antibody to IF, and serum unsaturated B₁₂ binding capacity. *Blood J. Hematol.* **25**: 875.
24. Allen, R. H., and C. S. Mehlman. 1973. Isolation of gastric vitamin B₁₂ binding proteins using affinity chromatography. II. Purification and properties of hog intrinsic factor and hog non-intrinsic factor. *J. Biol. Chem.* **248**: 3670.
25. Allen, R. H., and P. W. Majerus. 1972. Isolation of vitamin B₁₂-binding proteins using affinity chromatography. III. Purification and properties of human plasma transcobalamin II. *J. Biol. Chem.* **247**: 7709.
26. Allen, R. H., and P. W. Majerus. 1972. Isolation of vitamin B₁₂-binding proteins using affinity chromatog-

- raphy. II. Purification and properties of a human granulocyte vitamin B₁₂-binding protein. *J. Biol. Chem.* **247**: 7702.
27. Steck, T. L., and D. F. H. Wallach. 1965. The binding of kidney bean phytohemagglutinin by Ehrlich ascites carcinoma. *Biochim. Biophys. Acta.* **97**: 510.
 28. Holdsworth, E. S. 1961. The isolation and properties of intrinsic factor and vitamin B₁₂ binding substances from pig pylorus. *Biochim. Biophys. Acta.* **51**: 295.
 29. Ellenbogen, L., and D. R. Highley. 1967. Hog intrinsic factor. I. Isolation of vitamin B₁₂-binding fractions from hog pylorus. *J. Biol. Chem.* **242**: 1004.
 30. Irvine, W. J. 1966. Immunoassay of gastric intrinsic factor and the titration of antibody to intrinsic factor. *Clin. Exp. Immunol.* **1**: 99.
 31. Cooper, B. A., and W. B. Castle. 1960. Sequential mechanisms in the enhanced absorption of vitamin B₁₂ by intrinsic factor in the rat. *J. Clin. Invest.* **39**: 199.
 32. Ardeman, S., I. Chanarin, and V. Berry. 1965. Studies on human gastric intrinsic factor. (Observations on its possible absorption and enterohepatic circulation). *Br. J. Haematol.* **11**: 11.
 33. Cooper, B. A., and J. J. White. 1968. Absence of intrinsic factor in human portal plasma during ⁵⁷Co B₁₂ absorption in man. *Br. J. Haematol.* **14**: 73.
 34. Toskes, P. P., J. Hansell, J. Cerda, and J. J. Deren. 1971. Vitamin B₁₂ malabsorption in chronic pancreatic insufficiency. *N. Engl. J. Med.* **284**: 627.
 35. Toskes, P. P., and J. J. Deren. 1972. The role of the pancreas in vitamin B₁₂ absorption: studies of vitamin B₁₂ absorption in partially pancreatectomized rats. *J. Clin. Invest.* **51**: 216.
 36. Toskes, P. P., J. J. Deren, and M. E. Conrad. 1973. Trypsinlike nature of the pancreatic factor that corrects vitamin B₁₂ malabsorption associated with pancreatic dysfunction. *J. Clin. Invest.* **52**: 1660.